Vasopressin was among the first mammalian hormonal peptides to be identified and to have its structure determined1. Its only undisputed physiological role is as a circulating neurohypophyseal antidiuretic hormone. Other notable effects of vasopressin on peripheral tissues include contraction of vascular smooth muscle, leading to elevation of blood pressure, and activation of glycogenolysis in liver. It has long been clear that vascular smooth muscle and hepatocytes are relatively insensitive to the low concentrations of vasopressin normally present in the circulation, and the physiological significance of their responses has therefore been in doubt. We now report that a new bioactive and immunoreactive vasopressin-like peptide (VLP) is widely distributed in the sympathetic nervous system of mammals, both in the principal noradrenergic neurones of ganglia and in nerve fibres innervating peripheral tissues. In addition to other peptides described in the mammalian sympathetic nervous system2, VLP must be considered as a possible mediator of the non-adrenergic responses to sympathetic activation. Moreover, many of the effects previously attributed to circulating vasopressin may be neurally evoked.
Subscribe to Journal
Get full journal access for 1 year
only $3.83 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Du Vigneaud, V. et al. J. Am. chem. Soc. 25, 4879–4880 (1953).
Lundberg, J. M. et al. Proc. nain. Acad. Sci. U.S.A. 79, 1303–1307 (1982).
Schultzberg, M., Hokfelt, T. & Lundberg, J. in Regulatory Peptides of Gut and Brain (ed. Gregory, R.) 309–313 (Churchill Livingstone, London, 1982).
Kessler, J. A., Adler, J. A. Bohn, M. C. & Black, I. B. Science 214, 335–336 (1981).
Valtin, H., Schroeder, A., Benirschke, K. & Sokol, H. W. Nature 196, 1109–1110 (1962).
Creba, J. A. et al. Biochem. J. 212, 733–749 (1983).
Berridge, M. J., Downes, C. P. & Hanley, M. R. Biochem. J. 206, 587–595 (1982).
Kirk, C. J. Cell Calcium 3, 399–411 (1982).
Michell, R. H. et al. in Inositol and Phosphoinositides (eds Bleasdale, J. E., Eichberg, J. & Hauser, G.) (Humana, New York, in the press).
Lundberg, J. M. & Hokfelt, T. Trends Neurosci. 6, 325–333 (1983).
Rosenfeld, M. G. et al. Nature 304, 129–136 (1983).
Fisher, L. A. et al. Nature 305, 534–536 (1983).
Jard, S. in Cellular Receptors for Hormones and Neurotransmitters (eds Schulster, D. & Levitski, A.) 253–266 (Wiley, Chichester, 1980).
McGrath, J. C. J. Physiol., Lond. 283, 23–39 (1978).
Gamse, R., Wax, A., Zigmond, R. E. & Leeman, S. E. Neuroscience 6, 437–441 (1981).
Schultzberg, M. Neuroscience 8, 363–374 (1983).
Lightman, S. L. & Forsling, M. Clin. Endocr. 12, 39–46 (1980).
Tramu, G., Pillez, A. & Leonardelli, J. J. Histochem. Cytochem. 26, 322–324 (1978).
About this article
Cite this article
Hanley, M., Benton, H., Lightman, S. et al. A vasopressin-like peptide in the mammalian sympathetic nervous system. Nature 309, 258–261 (1984). https://doi.org/10.1038/309258a0
Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate
World Journal of Urology (2019)
Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders
Current Hypertension Reports (2018)
Vasopressin-dependent Myogenic Cell Differentiation Is Mediated by Both Ca2+/Calmodulin-dependent Kinase and Calcineurin Pathways
Molecular Biology of the Cell (2005)
Systemic and cavernous plasma levels of vasopressin in healthy males during different functional conditions of the penis
Urological Research (2003)